Done sou Salè H1B

Akèy › Anplwayè › Ideaya Biosciences Inc.

Ideaya Biosciences Inc.: Salè H-1B ak pajon

Ideaya Biosciences Inc. depoze 16 aplikasyon kondisyon travay pou visa H-1B ak visa ki gen rapò nan ane fiskal 2023–2026; sètifye: 16. Medyèn salè yo ofri a: $157,178.

Demann (LCA)16
Certifye16
Adrès anplwayèSouth San Francisco, CA
Anplwayè H-1B depannNon
Salè medyan ofri$157,178
Mwatye salè yo$116,346–$175,291
10yèm–90yèm pousantaj$107,800–$242,000

Èske Ideaya Biosciences Inc. pajone visa H-1B?

Ideaya Biosciences Inc. depoze 16 aplikasyon kondisyon travay nan ane fiskal 2023–2026, dènye a soumèt sou Apr 30, 2026. Yon LCA se premye etap yon demann H-1B, konsa anplwayè a pajone oswa prepare pou pajone travayè H-1B; li pa garanti pajon pou okenn travay espesifik. Tcheke lis travay pwòp anplwayè a.

Salè pa tit travay

Tit travayLCASalè medyan
Clinical Trial Manager3$161,508
Principal Research Associate3$105,000
Principal Research Scientist, Medicinal Chemistry2$158,988
Principal Research Associate, Translational Scienc1$110,600
Principal Research Scientist1$119,517
Senior Clinical Biomarker Scientist1$116,438
Senior Research Scientist, Medicinal Chemistry1$143,136
Director, Drug Safety Operations/Science and Compliance1$206,190
Medical Director, Patient Safety & Pharmacovigilance1$268,000
Director, Field Operations & Data Management1$216,000
Sr Director, Market Research and Competitive Intelligence1$272,397

Aplikasyon pa ane fiskal

Ane fiskalLCASalè medyan
FY20234$129,787
FY20242$134,092
FY20257$152,984
FY20263$268,000

Nivo salè prevanlan

Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.

Kote travay yo ye

Okipasyon

Dènye aplikasyon yo

Tit travaySalè bazKoteSoumètDat kòmansmanEstati
Sr Director, Market Research and Competitive Intelligence$272,397–$324,000
Nivo IV
Newark, CAApr 30, 2026May 18, 2026Certifye
Director, Field Operations & Data Management$216,000–$267,000
Nivo IV
South San Francisco, CAApr 17, 2026May 4, 2026Certifye
Medical Director, Patient Safety & Pharmacovigilance$268,000–$331,000
Nivo IV
South San Francisco, CAApr 17, 2026May 4, 2026Certifye
Clinical Trial Manager$161,371–$190,000South San Francisco, CASep 18, 2025Feb 23, 2026Certifye
Principal Research Associate$116,069–$146,500South San Francisco, CAJun 23, 2025Oct 31, 2025Certifye
Principal Research Scientist, Medicinal Chemistry$152,984–$190,550
E-3 · Nivo IV
South San Francisco, CAJun 3, 2025Nov 12, 2025Certifye
Principal Research Scientist, Medicinal Chemistry$164,991–$173,553
Nivo IV
South San Francisco, CAMar 24, 2025Sep 22, 2025Certifye
Director, Drug Safety Operations/Science and Compliance$206,190–$256,190
Nivo III
South San Francisco, CAJan 14, 2025Feb 3, 2025Certifye
Clinical Trial Manager$163,184–$189,500South San Francisco, CASep 5, 2024Jan 25, 2025Certifye
Principal Research Associate$101,816–$153,370
Nivo II
South San Francisco, CAMay 2, 2024Oct 1, 2024Certifye, apre retire
Principal Research Associate$105,000–$121,072
Nivo II
South San Francisco, CAJul 19, 2023Jan 13, 2024Certifye, apre retire
Senior Research Scientist, Medicinal Chemistry$143,136–$190,550
E-3 · Nivo IV
South San Francisco, CAJul 11, 2023Nov 12, 2023Certifye
Senior Clinical Biomarker Scientist$116,438–$162,466
Nivo II
South San Francisco, CAJun 21, 2023Dec 21, 2023Certifye
Clinical Trial Manager$161,508–$181,508South San Francisco, CADec 12, 2022Dec 19, 2022Certifye
Principal Research Associate, Translational Scienc$110,600–$142,388
Nivo III
South San Francisco, CAOct 14, 2022Oct 31, 2022Certifye
Principal Research Scientist$119,517–$185,000
Nivo IV
South San Francisco, CASep 27, 2022Oct 15, 2022Certifye, apre retire

Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).